Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-24T15:57:09.000Z","dateModified":"2026-07-24T15:59:26.000Z","description":"Tarsus experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. Eva Casas/iStock via Getty Images Tarsus Pharmaceuticals, Inc. (TARS) is three years into the launch of Xdemvy (lotilaner) for Demodex blepharitis and has seen its first decrease in sales from a prior quarter.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-24T15:57:09.000Z","dateModified":"2026-07-24T15:59:26.000Z","description":"Tarsus experienced a dip in net product sales in Q1'26, relative to
- ▪Eva Casas/iStock via Getty Images Tarsus Pharmaceuticals, Inc. (TARS) is three years into the launch of Xdemvy (lotilaner) for Demodex blepharitis and has seen its first decrease in sales from a prior quarter.
Seeking Alpha files mainly under finance. We currently carry 6,220 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925353-tarsus-pharmaceuticals-q226-rebound-in-sales-possible-catalysts-aprroaching"},"author":{"@type":"Person","name":"Biotech…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
